Abbott Laboratories
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert Ford
- Full Time Employees
- 115,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 100 Abbott Park Road Abbott Park IL United States of America 60064-6400
- IPO Date
- Mar 17, 1980
- CIK
- 0000001800
- Website
- abbott.com
- Similar Companies
- Business
- Abbott Laboratories (NYSE: ABT) develops, manufactures, and sells a broad range of health care products worldwide. The company operates through four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices; its core offerings include branded generic pharmaceuticals such as Branded generics in emerging markets, anti-infectives, and gastrointestinal drugs; diagnostics encompassing point-of-care testing systems like i-STAT, molecular diagnostics via Alinity platforms, rapid diagnostics under BinaxNOW and Determine brands, and core laboratory instruments; nutritional products including pediatric formulas like Similac and Pediasure, adult nutritionals such as Ensure and Glucerna, and medical foods; as well as medical devices featuring cardiovascular and neuromodulation devices including FreeStyle Libre continuous glucose monitoring systems, Aveir leadless pacemakers, TactiFlex ablation catheters, and structural heart devices like Amplatzer occluders. Abbott serves health care professionals, consumers, hospitals, laboratories, and governments across more than 100 countries, with principal manufacturing facilities in the United States, Europe, Asia, and Latin America. Founded in 1888 and headquartered in Abbott Park, Illinois, the company maintains a diversified portfolio without notable subsidiaries or parent relationships impacting its core structure. In recent developments within the last two years, Abbott completed the acquisition of Cardiovascular Systems, Inc. in 2024 to expand its cardiovascular portfolio; launched the FreeStyle Libre 3 integrated continuous glucose monitoring sensor in multiple markets including the U.S.; introduced the AVEIR DR dual chamber leadless pacemaker system and the TactiFlex Sensor Enabled Ablation Catheter; formed strategic partnerships for digital health integrations and expanded diagnostics manufacturing capacity amid global demand surges; and reported strong growth in its diabetes and cardiovascular segments during 2025 earnings.
Company News
Envestnet Asset Management Inc. Sells 1,228,773 Shares of Abbott Laboratories $ABT
Abbott Laboratories $ABT Shares Sold by Engineers Gate Manager LP
Rep. Rick W. Allen Acquires Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM) Shares
Broadcom (NASDAQ:AVGO) Shares Bought Rep. Rick W. Allen
Rep. Rick W. Allen Unloads Rollins, Inc. (NYSE:ROL) Shares
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Abbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health
Abbott Laboratories vs. Intuitive Surgical: Recent Quarterly Revenue Trends Reveal a Classic Investing Truth
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
3 Dividend Stocks to Buy and Hold for 10 Years
The Dividend Kings Ranked By Quality Scores (September 2026)
Why Wall Street Is Becoming Even More Bullish About This Dividend King
Abbott declares 411th consecutive quarterly dividend
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
Is AbbVie the Best Dividend King to Buy in September?
Bank of America Corp DE Acquires Shares of 17,672,543 Abbott Laboratories $ABT
Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside
Abbott (ABT) Rises As Market Takes a Dip: Key Facts
Abbott to pay $384 mln over contaminated infant formula allegations, US Justice Dept says
Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall